Artelo Biosciences, Inc.
ARTL
$7.16
-$0.15-2.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.98M | 5.42M | 4.48M | 4.03M | 4.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.40M | 12.43M | 10.54M | 9.90M | 10.11M |
| Operating Income | -11.40M | -12.43M | -10.54M | -9.90M | -10.11M |
| Income Before Tax | -12.88M | -12.49M | -10.50M | -9.72M | -9.83M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.88 | -12.49 | -10.50 | -9.72 | -9.83 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.88M | -12.49M | -10.50M | -9.72M | -9.83M |
| EBIT | -11.40M | -12.43M | -10.54M | -9.90M | -10.11M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -47.92 | -62.73 | -57.15 | -53.88 | -54.85 |
| Normalized Basic EPS | -28.90 | -39.32 | -36.06 | -34.29 | -35.27 |
| EPS Diluted | -47.92 | -62.73 | -57.15 | -53.88 | -54.85 |
| Normalized Diluted EPS | -28.90 | -39.32 | -36.06 | -34.29 | -35.27 |
| Average Basic Shares Outstanding | 1.31M | 815.90K | 732.90K | 720.90K | 716.20K |
| Average Diluted Shares Outstanding | 1.31M | 815.90K | 732.90K | 720.90K | 716.20K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |